Tirzepatide Weight Loss Medication

A Revolutionary Solution at My Concierge MD

Struggling to lose weight despite trying diets and exercise?

We offer Tirzepatide injections like Mounjaro and Zepbound—FDA-approved medications for managing type 2 diabetes that have shown incredible potential for weight loss.

Whether you’re dealing with obesity or looking to improve your overall health, Tirzepatide may be the breakthrough you need.

What is Tirzepatide?

Tirzepatide belongs to a unique class of medications that activate GIP and GLP-1 receptors in the body. These receptors regulate blood sugar levels, reduce appetite, and slow digestion, helping you eat less and feel fuller for longer.

Clinical trials have demonstrated its impressive ability to support weight loss, making it a promising option for managing obesity and lifestyle changes.

How Does Tirzepatide Work for Weight Loss?

Tirzepatide aids weight loss by targeting multiple mechanisms in the body:

• Appetite Suppression: Sends signals to the brain to curb hunger and cravings.
• Slowed Digestion: Keeps food in the stomach longer, promoting a feeling of fullness.
• Metabolic Boost: Reduces blood sugar and glucagon levels, encouraging the body to burn fat for energy.

In clinical trials, participants experienced significant weight loss, with the highest dose leading to a 22.5% reduction in body weight—results comparable to bariatric surgery!

Tirzepatide Dosing for Weight Loss

Treatment begins with a low dose of 2.5 mg once a week to help your body adjust to the medication and reduce the likelihood of gastrointestinal side effects like nausea. This initial phase lasts for 4 weeks.

Tirzepatide dosing is gradually increased every 4 weeks to maximize its effectiveness while ensuring your comfort:

• Week 1–4: 2.5 mg
• Week 5–8: 5 mg
• Week 9–12: 7.5 mg
• Week 13–16: 10 mg
• Week 17–20: 12.5 mg
• Week 21 and Beyond 15 mg (maximum dose)

This progressive approach allows your body to adapt, promoting sustainable weight loss with minimal side effects.

Is Tirzepatide FDA-Approved for Weight Loss?

While Mounjaro is FDA-approved for type 2 diabetes, its weight-loss benefits have been widely recognized. In November 2023, Zepbound, a new tirzepatide, received FDA approval specifically for weight loss. Both medications work similarly to lower blood sugar and suppress appetite.

What Can You Expect from Tirzepatide?

Patients using Tirzepatide report:

• 15-20% body weight loss over 72 weeks.
• Improved cholesterol, blood pressure, and cardiovascular health.
• Enhanced energy levels and overall well-being.

When combined with a calorie-reduced diet and physical activity, tirzepatide offers a sustainable path to weight loss goals.

Overcoming the Tirzepatide Shortage

Due to the high demand for Mounjaro and Zepbound, there is a nationwide shortage of these medications. At My Concierge MD, we partner with reputable compounding pharmacies to provide high-quality, compounded Tirzepatide at a fraction of the cost.

How to Get Started

Getting Tirzepatide for weight loss is simple and convenient with My Concierge MD:

1. Schedule a Consultation: Book a virtual or in-person visit with our MD and Nutritionist for $450.
2. Receive Your Prescription: We’ll help you get Tirzepatide or compounded alternatives shipped directly to your door.
3. Affordable Pricing:
   • 1-Month Supply of Compounded Tirzepatide: $850
   • 3-Month Supply of Compounded Semaglutide: $999

Who is a Good Candidate for Tirzepatide?

Tirzepatide is ideal for adults with:

• Type 2 diabetes or insulin resistance.
• Obesity (BMI ≥30) or overweight with weight-related conditions such as high cholesterol, hypertension, or fatty liver disease.
• A commitment to healthy lifestyle changes like improved diet and exercise.

Tirzepatide is not suitable for individuals with:

• Type 1 diabetes or pancreatitis.
• Medullary thyroid carcinoma (MTC) or a family history of thyroid cancer.
• Severe gastrointestinal conditions or allergies to the medication.

Tirzepatide Side Effects

While effective, Tirzepatide may cause some side effects:

• Common: Nausea, vomiting, diarrhea, constipation, fatigue.
• Rare but Serious: Hypoglycemia, thyroid tumors, pancreatitis, or kidney issues.

Our team monitors your progress closely to minimize risks and adjust your treatment as needed.

Tirzepatide vs Semaglutide​, Which One is Better for Weight Loss?

Tirzepatide may be better suited for those with significant weight loss goals and type 2 diabetes, while Semaglutide is an excellent choice for those focusing on weight management without diabetes. The right choice depends on your medical history, lifestyle, and goals.

Weight Loss Results

• Tirzepatide: Clinical trials show an average weight loss of 15-22.5% of total body weight, with some participants losing up to 52 pounds over 72 weeks.
• Semaglutide: Participants in clinical studies lost an average of 10-15% of their starting body weight, with Wegovy users achieving up to 35 pounds of weight loss.

Ready to Transform Your Health?

Take the first step toward a healthier, happier life with Tirzepatide injections. Contact My Concierge MD at 310-299-8959 or book online for your personalized weight loss program. With expert guidance, ongoing support, and proven treatments, we’re here to help you achieve your goals.

References

Gadde KM, Martin CK, Berthoud HR, Heymsfield SB. Obesity: Pathophysiology and Management. J Am Coll Cardiol. 2018;71(1):69-84. doi:10.1016/j.jacc.2017.11.011

Jastreboff AM, Aronne LJ, Ahmad NM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. 2022;387(3):205-216. doi:https://doi.org/10.1056/nejmoa2206038

Tirzepatide (Mounjaro) for type 2 diabetes. Med Lett Drugs Ther. 2022;64(1654):105-107.

Trujillo J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J Clin Pharm Ther. 2020;45 Suppl 1(Suppl 1):43-60. doi:10.1111/jcpt.13225

Tirzepatide. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; June 20, 2022.

Bethel MA, Diaz R, Castellana N, Bhattacharya I, Gerstein HC, Lakshmanan MC. HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression. Diabetes Care. 2021;44(1):290-296. doi:10.2337/dc20-1815

Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022;27(13):4315. Published 2022 Jul 5. doi:10.3390/molecules27134315